Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial

PUMA BIOTECHNOLOGY, INC.

Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.
Bench trial on equitable claims ruled in Wyeth's favor; all AstraZeneca defenses rejected.
Puma maintains contractual rights to recover monetary damages under license with Pfizer.
Post-trial motions pending; AstraZeneca seeks new trial, Wyeth seeks supplemental damages and ongoing royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.